Friedman Billings Adds Pharmion (PHRM) a biotech Top Pick
Tweet
Share
E-mailGet Alerts PHRM Hot Sheet
Price: $12.00 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 53
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 53
Join SI Premium – FREE
CONTRIBUTOR http://notablecalls.blogspot.com
FBR notes Pharmion (NASDAQ: PHRM) joins CELG as a biotech Top Pick on the FBR Top Picks list. Firm thinks PHRM should be trading at $32 in the next 12 months, implying 37% appreciation potential. They reach their $32 target by multiplying 2010 EPS estimate of $1.61 by a multiple of 30x and discounting at 20%. Firm's 2010 EPS assumes revenue of $482M, but there could be upside to this number; the company recently guided for revenues to range from $600M to $825M in 2010.
Drivers for outperformance include: further evidence from monthly data that Vidaza can survive - and even grow " with Dacogen now on the market, key presentations at ASH that position Vidaza for further growth, and 1H07 filings in Europe on thalidomide (calling attention to the possibility that approval could double sales from its current run rate of $76 million) and satraplatin in prostate cancer.
Notablecalls: Expect to see some mild buy interest following the call.
http://notablecalls.blogspot.com
FBR notes Pharmion (NASDAQ: PHRM) joins CELG as a biotech Top Pick on the FBR Top Picks list. Firm thinks PHRM should be trading at $32 in the next 12 months, implying 37% appreciation potential. They reach their $32 target by multiplying 2010 EPS estimate of $1.61 by a multiple of 30x and discounting at 20%. Firm's 2010 EPS assumes revenue of $482M, but there could be upside to this number; the company recently guided for revenues to range from $600M to $825M in 2010.
Drivers for outperformance include: further evidence from monthly data that Vidaza can survive - and even grow " with Dacogen now on the market, key presentations at ASH that position Vidaza for further growth, and 1H07 filings in Europe on thalidomide (calling attention to the possibility that approval could double sales from its current run rate of $76 million) and satraplatin in prostate cancer.
Notablecalls: Expect to see some mild buy interest following the call.
http://notablecalls.blogspot.com
You May Also Be Interested In
- Wells Fargo Downgrades Canada Goose (GOOS:CN) (GOOS) to Underweight
- Wolfe Research Starts Jersey Mike's Subs (JMKE) at Peerperform
- CTS Eventim (EVD:GR) PT Raised to EUR100 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst Comments, ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
